News
Cytokinetics prepares to take on BMS’ Camzyos in HCM
Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myer
